Full-Time

Senior Manager

Medical Content Product Owner, Medcomms Vault

Posted on 2/21/2026

Deadline 4/30/26
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Global biopharma researching, developing, delivering medicines

Compensation Overview

$135.3k - $164k/yr

+ Incentive Cash + Stock Opportunities

Company Historically Provides H1B Sponsorship

Princeton, NJ, USA

In Person

On-site protocol suggests occupancy type unknown for this role (could be 100% onsite or hybrid); no explicit hybrid/remote details.

Category
Product (1)
Required Skills
Agile
Forecasting
Product Management
Data Analysis
Requirements
  • 7+ years in product management or platform ownership in life sciences, with deep experience in content management for Medical Affairs/Medical Information
  • Hands-on experience with Veeva Vault (preferably MedComms), including workflows, lifecycles, roles/permissions, metadata, and content governance
  • Proven ability to define product strategy, build outcome-oriented roadmaps, and manage prioritized backlogs (epics, stories, acceptance criteria)
  • Experience integrating AI capabilities (enhance content authoring, search, tagging, or workflow automation) into content management platforms or medical information systems
  • Capable of working cooperatively across boundaries and within a matrix to achieve results
  • Ability to deliver complex, highly integrated systems to one or multiple geographies and business units
  • Demonstrates strong presentation and influencing skills with key partners across functions/regions
Responsibilities
  • Own and articulate the product vision, strategy, and multi-release roadmap for Veeva Vault MedComms and adjacent Medical content capabilities, to enable efficiencies in Medical content lifecycle
  • Champion education and visibility across the Medical Content domain, enabling collaborative alignment that shapes the roadmap and drives higher customer engagement and satisfaction
  • Deliver innovative solutions, leveraging Ai and automation, to increase speed of content delivery, in a compliant manner
  • Pilot and scale proven prototypes and use cases
  • Lead product discovery with Medical/MI stakeholders and field users; translate insights into epics, user stories, and acceptance criteria
  • Partner with Commercial content teams to make space for cross-domain solutions that have high benefit impact for both Commercial and Medical content
  • Apply Agile ways of working to rapidly prototype solution ideas to validate applicability and feasibility
  • Prioritize and groom the backlog to balance regulatory compliance, business value, risk, and technical feasibility; run effective PI/iteration planning in partnership with Delivery.
  • Define product OKRs and KPIs (e.g., content cycle time, global-to-local reuse, adoption, search efficacy, field-medical engagement) and manage to outcomes
  • Ensure validated delivery (CSV/SDLC): author change controls, oversee test evidence, and lead release governance for triannual Vault updates and interim changes
  • Coordinate incident, problem, and demand management; drive RCA and preventive actions with vendors (e.g., Veeva) and internal teams
  • Partner with Solution Architecture on reference designs and integrations (e.g., Veeva CRM, Medical Information portals such as PhactMI/MIO, analytics/visualization, taxonomy services)
  • Steward content data model and metadata/taxonomy standards (scientific statements, references) to enable global consistency and reuse
  • Champion change management and enablement (communications, training, release notes), accelerating adoption and continuous improvement
  • Manage vendor relationships, SOWs/licensing inputs, and contribute to budgeting/forecasting for product areas
  • Understand content componentization and development of capabilities that set up foundational content to enable AI and automation in.
Desired Qualifications
  • Commercialization (Commercial + Medical) domain & digital capability solutions experience
  • 8+ years experience in Product management and/or technical product evolution
  • Understanding of content management and ability to define processes that span the content lifecycle
  • Excellent collaboration and communication skills, with the ability to build strong partnerships
  • Proactive, self-accountable, and takes initiative in identifying opportunities and forming projects to achieve those goals
  • Ability to clearly articulate and translate technical elements in business terms, and vice versa
  • Demonstrated ability to communicate, influence and partner with senior leaders
  • Ability to lead the analysis of complex business needs and translate them into deployable technology solutions by developing/owning/managing the solution architecture & design of the same
  • Ability to scan technical landscape for cutting-edge technology solutions and be able to recommend the best solution for the digital capability area including pros/cons, technical, functional, organizational fit, and facilitating risk assessments
  • Strong stakeholder leadership across Medical Affairs, Medical Information, Field Medical, Compliance/QA, Architecture, and Engineering; excellent communication skills
  • Data-driven mindset with experience instrumenting and reporting product KPIs and using insights to guide iteration
  • Working knowledge of Veeva Vault and Veeva platforms. Hands-on configuration experience with Veeva systems and content authoring tools
  • Multiple implementations of digital capabilities in commercialization domain, with hands-on configuration experience
  • Working knowledge of different software-development lifecycle methodologies like AGILE etc
  • Demonstrated ability to support a dynamic culture of innovation and continuous improvement. Working knowledge of AL/ML technologies to drive automation
  • Potential to develop into an internally and externally recognized thought-leader in the field of IT Architecture & Solution Design for Content Capabilities

Bristol Myers Squibb develops and sells medicines for serious diseases, focusing on cancer, immune system disorders, and cardiovascular conditions. Its work starts with research and development to create new therapies, which are then approved by regulators before being used by doctors and patients; the company also offers generic versions and supports biosimilars to expand access. BMS differentiates itself with a broad portfolio of innovative medicines alongside affordable options and a strong emphasis on ESG and regulatory engagement. The goal is to improve patient health by delivering effective, affordable medicines and advancing sustainable healthcare globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth Portfolio averages 16% YoY growth over two years per Q1 2026 results.
  • Eliquis on Cost Plus Drugs at $345/30-day expands access from April 27.
  • FoundationOne CDx expansion detects MTAP deletion for targeted oncology therapy.

What critics are saying

  • Eliquis generics from Apotex erode $14.4B sales post-2026 patent expiry.
  • Revlimid sales plunge drives 5.1% revenue drop in next 12 months.
  • FDA revoked Krazati approval May 5, 2026, after failed NSCLC PFS trial.

What makes Bristol Myers Squibb unique

  • Mezigdomide plus carfilzomib beats Kd in SUCCESSOR-2 Phase 3 PFS for RRMM.
  • Sotyktu gains EU approval May 2026 for psoriatic arthritis post-POETYK trials.
  • Cobenfy switch study shows 8-week PANSS stability from atypicals in schizophrenia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

360Dx
Apr 21st, 2026
In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion.

In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion. NEW YORK - Foundation Medicine said Tuesday that it has expanded an ongoing collaboration with Bristol Myers Squibb to develop FoundationOne CDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month

Yahoo Finance
Apr 13th, 2026
Bristol Myers Squibb: 4.2% dividend yield and stable revenue at bargain valuation

Bristol Myers Squibb presents an attractive value investment in the pharmaceutical sector, with a forward price-to-earnings ratio of 9.5, significantly lower than competitors Johnson & Johnson (21) and Merck (24). The company offers a 4.2% dividend yield and has increased payouts for 17 consecutive years. Bristol reported $48.2 billion in revenue for 2025, with 2026 guidance between $46 billion and $47.5 billion, demonstrating consistency despite modest decline. However, the favourable valuation reflects investor concerns about slowing legacy portfolio revenue, which fell from $25.7 billion in 2024 to $21.8 billion in 2025. Key challenges include an upcoming patent cliff for Eliquis, its blood thinner generating $14.4 billion in 2025 sales, and the $1.5 billion acquisition of Orbital Therapeutics whilst carrying over $47 billion in debt.

Yahoo Finance
Apr 10th, 2026
Bristol Myers' Cobenfy hits $155M in first year, outpacing rival schizophrenia treatments

Bristol Myers Squibb's schizophrenia drug Cobenfy generated $155 million in sales during 2025, outpacing comparable treatments in its first year following FDA approval in September 2024. The medication represents the first new pharmacological approach to treating schizophrenia in decades. Recent phase II data presented at the Schizophrenia International Research Society Annual Congress showed adults with schizophrenia remained stable after switching to Cobenfy monotherapy over eight weeks, with low discontinuation rates and no dropouts due to lack of efficacy. Bristol Myers is pursuing label expansions across multiple indications, with ongoing phase III studies in Alzheimer's disease psychosis, agitation, cognitive impairment, bipolar I disorder and paediatric irritability associated with autism. The company expects Cobenfy to become a significant growth driver as legacy drugs face generic competition.

Buzzword News
Mar 30th, 2026
Bristol Myers Squibb adding 3 medications on TrumpRx.

Bristol Myers Squibb adding 3 medications on TrumpRx. Mar 30, 2026 - 14:01 EXCLUSIVE: Bristol Myers Squibb is launching three medications on TrumpRx.gov on Monday, FOX Business has learned. The three prescription drugs will each be offered at deep discounts that range from 40% to 90% off the retail price. The Princeton, New Jersey-based company's drug Sotyktu retails for $7,135.55 and will be offered through TrumpRx.gov for $743. That represents a 90% discount off what patients have been paying. Sotyktu treats adults with moderate-to-severe plaque psoriasis. Zeposia, which treats relapsing forms of multiple sclerosis, will be added at a discount of between 88% and 90%. The weekly injection to treat moderate-to-severe rheumatoid arthritis, Orencia SC, will be reduced by 40% from the retail price. A White House official said this is the latest big pharma company to offer reduced prices after the tariff pressure from President Donald Trump. The talks with pharmaceutical companies continue to be successful, with more medications added to the government website. Bristol Myers' additions come weeks after FOX Business reported that Amgen and GSK were added to the list of prescription drug manufacturers offering discounts on the government website. Amgen offers medications on the website that cut 80% off the retail price. Amjevita has an original price of $1,484, but will be available on TrumpRx.gov for $299. The medication treats rheumatoid arthritis, psoriasis and ulcerative colitis. Amgen also lists Aimovig and Repatha for discounts of 62%. GSK discounts Incruse at 55% off the retail price. The drug treats COPD and will be listed at $159.20. GSK lists Arnuity, Relenza and Anoro at discounts ranging from 10% to 51%. The White House is pushing ahead with announcements to TrumpRx.gov as Americans look for ways to cut medical costs. Under the Biden administration, Bureau of Labor Statistics data shows, prescription drug costs increased 10.4% from January 2021 to January 2025. Under the Trump administration, prescription drug prices increased 0.2% from January 2025 through the latest data from February 2026.

Insider Monkey
Mar 30th, 2026
Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment.

Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment. Published on March 30, 2026 at 2:07 am by sultan khalid in news. Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Large Cap Stocks with Highest Dividends. Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company (NYSE:BMY) announced on March 20 that the U.S. Food and Drug Administration had approved the company's combination treatment for adults and adolescents aged 12 and older with previously untreated stage III or IV classical Hodgkin's lymphoma. The antitumor therapy, called Opdivo, had previously received the green light to treat various advanced or metastatic cancers, including melanoma, non-small cell lung cancer, and kidney cancer. The regulatory authority's decision is based on a late-stage study of 994 patients, which demonstrated that the treatment significantly improved progression-free survival compared with brentuximab vedotin. Hodgkin's lymphoma, also known as Hodgkin's disease, is the most common form of cancer in patients aged 15 to 19. It starts in white blood cells, which are part of the body's immune system, a cancer that starts in white blood cells. Monica Shaw, MD, Senior Vice President of Oncology Commercialization at Bristol-Myers Squibb Company (NYSE:BMY), stated: "These approvals represent a defining moment for people living with classical Hodgkin Lymphoma. In the U.S., we are particularly proud that Opdivo in combination with AVD now stands as an immunotherapy combination available for adults and pediatric patients, ages 12 and older, with previously untreated advanced disease. Concurrently, in the EU, Opdivo in combination with brentuximab vedotin has also achieved a milestone as the first immunotherapy combination for certain relapsed or refractory patients. These milestones reflect our continued commitment to advancing science that meaningfully improves the lives of patients and families worldwide." While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

INACTIVE